FY26 revenue growth of 20-30%
Management expects to deliver 20-30% revenue growth in FY26 driven by improving demand visibility and new product commercialization in agro and pharma segments.
TATVA / guidance tracker
Keep management guidance in view.
Tatva Chintan Pharma Chem · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Target revenue of ₹850-900 crore in 2.5-3 years
Company believes current expanded capacity can support ₹850-900 crore revenue, implying significant operating leverage from existing infrastructure investments.
EBITDA margin of 20-22% realistic for FY27
Management expects margins to reach 20-22% range by FY27 as new Dahej block removes production bottlenecks and reduces underutilization expenses currently weighing on profitability.
New agro intermediates to add ₹250-300 crore revenue by CY27
Three agro intermediates and three pharma intermediates expected to contribute additional ₹250-300 crore in calendar year 2027 on top of existing ~₹40 crore current run rate, with pharma ramp-up materializing from CY28.
FY27 Revenue Growth Target: 25%
Management maintained guidance of approximately 25% revenue growth for FY27 despite geopolitical headwinds, citing robust order visibility and multiple new product introductions. This guidance is supported by existing product momentum and new commercializations.
FY27 EBITDA Margin Guidance: 20-22%
EBITDA margin expected in the 20-22% range for FY27, up from 16.25% in Q4 FY26, driven by improved operational efficiency, higher plant utilization, and operating leverage as new products scale up.
Dahej Greenfield Commercialization: Early 2028
Groundbreaking expected within 60 days (mid-July 2025 target) with 18-20 month construction timeline targeting January-March 2028 for first commercial production. Phase 1 revenue potential of Rs 400-500 crore.
Semiconductor Chemicals Commercialization: Late 2028-Early 2029
First plant-scale batch dispatch in current quarter. Product undergoing multiple validation cycles at integrator and customer levels before final commercialization expected by end of 2028.